Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Privacy Policy  
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Adjunctive doxorubicin in feline mammary gland tumors
Mammary gland tumors in cats are rare compared with other species e.g. dogs - but if they are diagnosed they tend to be highly malignant. The therapy of choice is surgical removal as soon as possible. Does doxorubicin improve the prognosis? A very interesting retrospective study...

Medical records for 67 cats with histologically confirmed mammary gland adenocarcinomas treated with adjunctive doxorubicin from June 1994 through December 2002 were reviewed.

Data were examined to evaluate factors influencing disease-free interval (DFI) and survival time.

The Kaplan-Meier median survival time of cats that received surgery and doxorubicin was 448 days.

The Kaplan-Meier median DFI was 255 days.

Significant univariate prognostic factors for DFI included histological subtype, completion of initial chemotherapy, development of metastatic disease, and location of metastatic disease.

Significant univariate prognostic factors for survival included tumor volume, the development of metastatic disease, and location of metastatic disease.




Source: C. Andrew Novosad et al (2006): Retrospective Evaluation of Adjunctive Doxorubicin for the Treatment of Feline Mammary Gland Adenocarcinoma: 67 Cases. In: Journal of the American Animal Hospital Association 42:110-120 (2006)



Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Acute echocardiographic effects of sotalol in dogs with ventricular arrhythmias
Sotalol is a commonly used antiarrhythmic drug that may alter ventricular function. The objective of this recently published study was to determine the effect of sotalol on echocardiographic indices of ventricular systolic function in dogs with ventricular arrhythmias.
Thirty‐five client‐owned dogs with ventricular arrhythmias were enrolled.

  • Proteasome inhibitors for canine and human osteosarcomamembers
  • Pharmacokinetics of a novel mirtazapine transdermal ointment in catsmembers
  • Bacterial contamination in 50% dextrose vials after multiple puncturesmembers
  • Sotalol and the ventricular systolic function in dogs with ventricular arrhythmiasmembers
  • Life-threatening arterial haemorrhage during nephrectomymembers
  • Update to the chinchilla retinamembers
  • Vocal fold granulomas in brachycephalic dogsmembers
  • Extracellular vesicles in mammary cancer of dogs and catsmembers
  • Immunocytochemical assay using aqueous humor to diagnose feline infectious peritonitis members
  • Microbiota of traumatic, open fracture wounds and the mechanism of injury members
  • False-positive CT and radiography results for bronchial collapse in healthy dogsmembers
  • Variability of SDMA in apparently healthy dogsmembers


  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved